CRVS · Corvus Pharmaceuticals, Inc.

The thesis

Corvus Pharmaceuticals' soquelitinib case is a clinical bet that the late-2026 Angel eczema cohort settles; the shares closed at $10.65 on 22 October 2026, still 58.3% below the 52-week high of $25.52. A miss, or no report by 31 December 2026, breaks the dated catalyst the case rests on.

Corvus guided on 6 August 2026 that Angel Pharmaceuticals' first blinded atopic dermatitis (eczema) cohort would report late in 2026. The narrative is maturing: the 27 August 2026 lymphoma publication and the 30 September 2026 start of the hidradenitis suppurativa study are both past, and no new efficacy data has arrived since. The shares fell 17.6% over the three months to 22 October 2026, and the 14-day relative strength index (RSI) is 47.2, up from 31.2 on 9 October 2026 when the shares closed at $10.52.

The recovery condition from the earlier note, a weekly close above $14.16 before one below $12.50, has failed. The $10.65 close sits below both the $12.50 level and the $14.16 close of 28 August 2026. Searches of company news and analyst reports found no earnings, guidance, filing or price-target change dated after the earlier note of 10 October 2026.

Bullish and bearish views on Corvus Pharmaceuticals, Inc.

The bull case on Corvus Pharmaceuticals, Inc. (CRVS), in brief: Cash covers the planned trials. The bear case: The price remains under the recovery levels.

Bull case

• Cash covers the planned trials. Corvus held $215.2 million in cash, equivalents and marketable securities at 30 June 2026, including roughly $189.4 million of net proceeds from a first-quarter 2026 follow-on offering. Management guided runway into the second quarter of 2028 (company results, 6 August 2026).
• Early eczema data were strong. Final Phase 1 results in moderate-to-severe atopic dermatitis showed 75% of patients in the highest-dose, longest-duration cohort reached a 75% improvement in eczema severity (EASI-75), versus 20% on placebo (Corvus second-quarter results, 6 August 2026).
• Lymphoma responses are peer reviewed. The 27 August 2026 Blood publication announcement reported nine responses, six of them complete, among 24 patients with one to three prior treatment lines at 200 milligrams twice daily.
• The pipeline keeps widening. Corvus announced on 30 September 2026 that enrollment began in a Phase 1b study in hidradenitis suppurativa. Management called the registrational Phase 3 lymphoma trial and the Phase 2 eczema trial on track on 6 August 2026.

Bear case

• The price remains under the recovery levels. The $10.65 close of 22 October 2026 is below $12.50 and below the $14.16 close of 28 August 2026. The shares are 58.3% below the 52-week high of $25.52.
• Spending is rising fast. Research and development expense was $16.0 million in the quarter ended 30 June 2026, against $7.9 million a year earlier. Net loss was $18 million, against $8 million (company results, 6 August 2026).
• The company has already issued shares. The first-quarter 2026 follow-on offering raised about $189.4 million. Another equity raise before the 2028 runway ends would dilute holders.
• Controlled evidence is still missing. The Phase 1 eczema and lymphoma figures come from small groups. The Angel cohort is run by a privately held, 49%-owned affiliate in China, and the 9 June 2026 financing release said Corvus has limited ability to estimate Angel's cash runway.

Price setup

The shares closed at $10.65 on 22 October 2026, per adjusted daily closes. That is 17.6% lower than three months earlier and 58.3% below the 52-week high of $25.52. The close of $10.52 on 9 October 2026 was the low of the recent decline in the closes reviewed, and the shares have moved little since.

The RSI of 47.2 is neutral, so the oversold reading of 9 October 2026 has cleared without a rally above $12.50. Overhead levels are $12.50 and the $14.16 close of 28 August 2026. The invalidation level is a daily close below $9.50, under the 9 October 2026 close.

Crowding evidence is thin. The only recent news item is a 12 October 2026 repost of the second-quarter earnings call transcript, and an options-activity alert in healthcare names dated 1 July 2026 (Benzinga) is the last sign of heavy trader attention. No SEC filings or insider transactions turned up for the period.

Catalysts, next 30 days

• Later, by 31 December 2026: Angel's first blinded eczema cohort. Corvus guided this readout for late 2026. It falls outside the 30-day window but decides the case.

Elapsed catalysts

• ~5 November 2026, est.: third-quarter 2026 results. The date is an estimate based on the company's prior reporting pattern. The report shows cash, spending and whether the second-quarter 2028 runway guidance holds. (passed 1d ago)

What would change the view

The case breaks if Angel's first blinded eczema cohort misses its endpoints or does not report by 31 December 2026. It also breaks if the lymphoma trial stops at its guided 2027 futility analysis.

A financing that shortens the runway guided into the second quarter of 2028 would weaken it, because the company has already raised about $189.4 million this year. The price condition is a daily close below $9.50, under the 9 October 2026 close of $10.52.

A positive cohort readout on or before 31 December 2026 would strengthen the case. A third-quarter report that confirms the runway and shows spending in line with the second quarter would remove one risk.

What it trades with

Corvus has no product revenue, so the shares trade on trial results and financing news. They move with small-cap clinical-stage biotech more than with the S&P 500. Angel's China-run trials add a second source of news that Corvus does not control.